Voveran 50 GE Tablet (15) Information
Voveran 50 GE Tablet (15), a prescription drug, is manufactured in various forms such as Tablet. It is typically used for the treatment of Muscle Pain, Toothache, Rheumatic Pain. Other than this, Voveran 50 GE Tablet (15) has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Voveran 50 GE Tablet (15) is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Voveran 50 GE Tablet (15) as well, which are listed below. Normally, these side effects of Voveran 50 GE Tablet (15) are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Voveran 50 GE Tablet (15) has a Severe effect for pregnant women and Mild effect on lactating mothers. In addition, Voveran 50 GE Tablet (15)'s effects on the liver, heart and kidney are discussed below in the Voveran 50 GE Tablet (15) related warnings section.
Voveran 50 GE Tablet (15) can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Voveran 50 GE Tablet (15) in conditions like Stomach Infection, Skin Rash, Stroke. Other contraindications of Voveran 50 GE Tablet (15) have been discussed in the sections ahead.
Additionally, Voveran 50 GE Tablet (15) may also adversely react with other medicines. A complete list of these interactions is given below.
In addition to these precautions, you may also note that Voveran 50 GE Tablet (15) is safe while driving, and is is addictive in nature.
Voveran 50 GE Tablet (15) Benefits & Uses
Voveran 50 GE Tablet (15) is used to treat the following -
Main Benefits
- Muscle Pain (Read More - Home Remedies for Muscle Aches)
- Toothache (Read More - Home remedies for toothache)
- Rheumatic Pain
Other Benefits
- Headache
- Joint Pain (Read More - How to Relieve Joint Pain Naturally: Best Home Remedies)
- Osteoarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Gout (Read More - Home remedies for gout pain)
- Migraine (Read More - Home remedies for migraines)
- Leg Pain (Read More - Home remedies for leg pain and weakness)
- Body Pain (Read More - Home Remedies for Body Pain)
- Sciatica (Read More - Home Remedies for Sciatica: Alleviate Pain Naturally)
- Foot Pain (Read More - How to Ease Foot Pain at Home with Natural Techniques)
Voveran 50 GE Tablet (15) Dosage & How to Take
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Voveran 50 GE Tablet (15) Side Effects
Based on research, the following side effects have been observed when Voveran 50 GE Tablet (15) is used -
Severe
- Nephrotoxic
- Constipation (Read More - Home remedies for constipation)
- Diarrhoea
- Pancreatic inflammation
- Liver Damage
Moderate
- Fluid Retention
- पेट दर्द
- Arrhythimia
Mild
- Skin Rash (Read More - DIY Skin Rash Relief: Simple Home Remedies That Work)
- Nausea or vomiting
Voveran 50 GE Tablet (15) Related Warnings
-
Is the use of Voveran 50 GE Tablet (15) safe for pregnant women?
Pregnant women may get severe side effects after taking Voveran. If you are pregnant, do not take Voveran without a doctor's advice.
Severe -
Is the use of Voveran 50 GE Tablet (15) safe during breastfeeding?
Voveran may have very limited harmful effects for breastfeeding women.
Mild -
What is the effect of Voveran 50 GE Tablet (15) on the Kidneys?
There may be some severe side effects of Voveran on your kidney. Do not take it unless a doctor says so.
Severe -
What is the effect of Voveran 50 GE Tablet (15) on the Liver?
Voveran can cause side effects that could harm the liver. So medical advice before taking it is necessary.
Severe -
What is the effect of Voveran 50 GE Tablet (15) on the Heart?
Voveran may cause harmful effects on the heart. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
Moderate
Severe Interaction of Voveran 50 GE Tablet (15) with Other Drugs
Voveran 50 GE Tablet (15) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Voveran 50 GE Tablet (15) Contraindications
If you are suffering from any of the following diseases, you should not take Voveran 50 GE Tablet (15) unless your doctor advises you to do so -
- Edema
- Stomach Infection
- Gastrointestinal Bleeding
- Kidney Disease
- Skin Rash
- Heart Attack
- Stroke
- Asthma
- Anemia
- Heart Failure
- Liver Disease
- Peptic Ulcer
Frequently asked Questions about Voveran 50 GE Tablet (15)
-
Is this Voveran 50 GE Tablet (15) habit forming or addictive?
Forming a habit of Voveran 50 GE Tablet (15) has not been reported.
No -
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking Voveran 50 GE Tablet (15) since it will not make you feel sleepy.
Safe -
Is it safe?
Yes, but take Voveran 50 GE Tablet (15) only as per medical advice.
Safe, but take only on Doctor's advise -
Is it able to treat mental disorders?
No, Voveran 50 GE Tablet (15) is not used to treat mental disorders.
No
Voveran 50 GE Tablet (15) Interactions with Food and Alcohol
-
Interaction between Food and Voveran 50 GE Tablet (15)
There isn't any research available on the side effects of taking Voveran 50 GE Tablet (15) with food.
Unknown -
Interaction between Alcohol and Voveran 50 GE Tablet (15)
Taking Voveran 50 GE Tablet (15) with alcohol can have severely harmful effects on your health.
Severe
See all substitutes for Voveran
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 427-429
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 204
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Voltaren® (diclofenac sodium)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclofenac (diclofenac sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Solaraze® (diclofenac sodium)
